Masimo Corporation is part of the healthcare sector and trades as part of the medical instruments and equipment industry. The company CEO is Joseph E. Kiani. Masimo Corp is a medical technology company. The company develops, manufactures, and markets noninvasive monitoring technologies. Its product includes noninvasive blood constituent and brain and breath monitoring.
Previous Intraday Trading Performance:
The MASI stock showed a previous change of -0.53% with an open at 142.73 and a close of 141.32. It reached an intraday high of 143.66 and a low of 139.68.
The stock has a market cap of $7.5b with 53.4m shares outstanding, of which the float is 51.7m shares. Trading volume reached 285,617 shares compared to its average volume of 484,210 shares. Based on the current average volume and close price, the trading liquidity is good.
Historical Trading Performance:
Over the last five trading days, Masimo Corporation shares returned 5.04% and in the past 30 trading days it returned 8.58%. Over three months, it changed 7.94%. In one year it has changed 39.73% and within that year its 52-week high was 147.91 and its 52-week low was 96.14. MASI stock is 46.99% above its 52 Week Low.
Our calculations show a 200 day moving average of 123.04 and a 50 day moving average of 135.33. Currently MASI stock is trading 14.85% above its 200 day moving average.
The last annual fiscal EPS for the company was reported at 3.49 that ended on 31st of December 2018, which according to the previous close, that is a PE of 40.49. Based on 4 analyst estimates, the consensus EPS for the next quarter is 0.75. The TTM EPS is 3.02, which comes to a TTM PE of 46.79. Historically, the PE high was 56.90 and the PE low was 11.80. If the stock reached its PE low, that would represent a price of 35.64, which is a decrease of -74.78%.
Below was the last reported quarterly diluted earnings per share:
|1st||Qtr of 2019||(Reported on 05/06/2019):||0.87|
|4th||Qtr of 2018||(Reported on 02/26/2019):||0.83|
|3rd||Qtr of 2018||(Reported on 10/31/2018):||1.02|
|2nd||Qtr of 2018||(Reported on 08/01/2018):||0.79|
|1st||Qtr of 2018||(Reported on 05/02/2018):||0.82|
Base on our calculations, the intrinsic value per share is 95.17, which means it may be overvalued by -48.49%.
Indicators to Watch:
The current calculated beta is 1.10.
Based on last reported financials, the company’s return on equity is 22.27%, return on assets is 18.53%, profit margin is 22.49%, price-to-sales is 8.64 and price-to-book is 7.54.
All scores are out of six:
1 :Valuation Score
4 :Past Performance Score
6 :Financial Strength Score
2 :Future Growth Score
0 :Dividend Score
3 :Overall Score